This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Ron Birnbaum
University of California, San Francisco, School of Medicine

JAMA. 1997;278(11):897-898.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—It is bad enough that medical journals accept advertisements from pharmaceutical companies, as advertisements should fundamentally play no role in clinical decision making. It is worse when an issue of a journal that contains an article evaluating the efficacy and safety of a specific drug also includes advertisements from manufacturers of the drug in question.

The Editorial by Dr Rennie¹ confronts the shameful with-holding of an article² on the bioequivalence of various levothyroxine preparations by the legal bullying of a manufacturer that stood to lose millions by its publication. How galling is it then that the same issue which—correctly, albeit rather sanctimoniously—demonstrates the insidiousness of conflicts arising from partnerships between science and industry also contains 2 advertisements³ from another levothyroxine manufacturer that stands to gain in market share as a result of the article by Dong et al and the well-earned criticism of Knoll Pharmaceutical Company . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?